OncoPharm PARAMOUNT - Maintenance Pemetrexed
Oct 3, 2025
Explore the groundbreaking PARAMOUNT study, which solidified maintenance pemetrexed's role in treating non-small cell lung cancer. Delve into the biology behind why this drug excels in non-squamous tumors. Hear about historical trials and the switch maintenance concept that emphasizes the importance of tailored treatment. Discover the improved survival rates from the study, the comparison to other therapies, and the ongoing impact of these findings on modern maintenance strategies. It's a deep dive into how effective dosing can change patient outcomes!
AI Snips
Chapters
Transcript
Episode notes
Host Frames Landmark Series
- John Bazar introduces the Landmarks of OncoPharm series and frames PARAMOUNT as a practice-changing trial.
- He connects the episode to prior discussions and the series' goal of revisiting influential studies.
PARAMOUNT Changed Maintenance Practice
- PARAMOUNT solidified pemetrexed continuation maintenance for non-squamous NSCLC after platinum induction.
- The trial showed PFS benefit and later an OS improvement of about three months versus placebo.
Histology Drives Pemetrexed Use
- Earlier work (Scagliotti) showed pemetrexed benefits specifically in non-squamous histology due to biology like thymidylate synthase differences.
- This histology-specific activity motivated using pemetrexed in non-squamous induction and maintenance strategies.